Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Sun S, Yu F, Xu D, Zheng H, Li M. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. Biochim Biophys Acta Rev Cancer. 2022 03; 1877(2):188700.
-
Chen Y, Vargas SM, Smith TC, Karna SLR, MacMackin Ingle T, Wozniak KL, Wormley FL, Seshu J. Borrelia peptidoglycan interacting Protein (BpiP) contributes to the fitness of Borrelia burgdorferi against host-derived factors and influences virulence in mouse models of Lyme disease. PLoS Pathog. 2021 04; 17(4):e1009535.
-
Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
-
Bermel RA, Waubant E, Pardo G, Bass A, Repovic P, Newsome S, Lindsey JW, Kile D, Pradhan A, Musch B, Zabeti A. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715.
-
Anadani N, Hyland M, Cruz RA, Lisak R, Costello K, Major EO, Jassam Y, Meltzer E, Varkey TC, Parsons MS, Goodman AD, Graves JS, Newsome S, Zamvil SS, Frohman EM, Frohman TC. Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2021 01; 8(1).
-
Schwier NC, Cornelio CK, Epperson TM. Managing acute and recurrent idiopathic pericarditis. JAAPA. 2020 Jan; 33(1):16-22.
-
Houssiau FA, Thanou A, Mazur M, Ramiterre E, Gomez Mora DA, Misterska-Skora M, Perich-Campos RA, Smakotina SA, Cerpa Cruz S, Louzir B, Croughs T, Tee ML. IFN-a kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020 03; 79(3):347-355.
-
Royer DJ, Echegaray-Mendez J, Lin L, Gmyrek GB, Mathew R, Saban DR, Perez VL, Carr DJ. Complement and CD4+ T cells drive context-specific corneal sensory neuropathy. Elife. 2019 08 15; 8.
-
McLawhorn JM, Johnson AW, Kim KH, Addis K. Successful treatment of refractory epidermolysis bullosa acquisita with intravenous immunoglobulin and dapsone. Cutis. 2019 Aug; 104(2):E20-E21.
-
Chander DP, Loch MM, Cataland SR, George JN. Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 07 04; 381(1):92-94.